US FDA Panel Sees Benefits To OTC Pathogen Tests, But Urges Caution
Executive Summary
An FDA panel concluded Aug. 16 that the benefits of over-the-counter tests for influenza, strep throat and certain sexually transmitted infections would likely outweigh the risks. But the group urged developers to take care in ensuring that the test results were easy for patients to interpret.
You may also be interested in...
OTC Tests For Flu, Strep, STIs Up For Discussion At FDA Panel Meeting
Panelists will look at the benefits and risks of over-the-counter diagnostics for influenza, strep throat and sexually transmitted infections. The meeting is being held in response to sponsor queries about new test designs.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.